Skip to content

Consumer & Non-invasive BCI

Implantable BCIs are medical devices aimed at a small number of patients; only non-invasive BCIs have the potential to reach billions of users. This chapter covers three things: the capability boundary of today's consumer EEG devices, neural-sensing patents from mainstream brands like Apple AirPods, and the real-world status in 2024–2026 of the long-standing vision of "thought-to-text."

Relationship to Chapter 11. Chapter 11 is the commercial landscape for invasive BCI (the medical-device pathway); this chapter is the consumer landscape for non-invasive BCI (the consumer-electronics pathway). Their regulatory regimes differ entirely: FDA / NMPA demand years of clinical evidence for the former, while the latter mostly needs only FCC EMC and general consumer-electronics compliance. Both paths share a common paradox — signal quality is inversely correlated with product form — and that tension runs through the whole chapter: hiding electrodes inside earbuds / glasses / headbands forces signal-to-noise to drop several orders of magnitude below a Utah array, so the decoding side (Chapters 04, 05) must compensate heavily.

Recommended reading order. Consumer EEG Device Panorama first establishes the side-by-side comparison of Muse / Emotiv / OpenBCI / Neurable (research vs consumer, wet vs dry electrodes, sampling rate and channel count). Apple Neural Sensing Patents then zooms in on the most commercially significant player — AirPods EEG, granted in 2023, is expected to be the key product to bring consumer BCI mainstream. Finally, Thought-to-Text Status delivers a reality check: after twenty years of research, EEG-based thought typing is still not practical, the WER gap between invasive and non-invasive is wide, and multimodal fusion (eye-tracking + EMG + EEG) may be the only way to break the bandwidth ceiling.

This chapter covers:

评论 #